Potential Molecular Targets and Therapeutics in Triple-Negative Breast Cancer 2023

Dear Colleagues,

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks any targeted therapy, and despite current improvements in the treatment of breast cancer patients, fewer drugs have been approved and are available to these patients, especially those with metastatic TNBC. The first-line treatment options for these patients are chemotherapies which, despite their toxicity, are not very successful treatments, as often patients’ compliance with these treatments is low, and moreover, chemotherapies cannot overcome tumour resistance.

This Special Issue aims to integrate recent improvements in finding molecular targets and innovative approaches in the treatment of metastatic TNBC with an effort to expand the knowledge on a wide range of topics in this field. I would like to sincerely invite you to contribute to this Special Issue with your research articles and reviews, which can include, but are not limited to, the following topics: molecular targets, signalling pathways, miRs, gene expression and multigene predictors, role of epigenetics, stem cells, single or combination treatments, targeted treatments and novel targeted formulations, animal models, and clinical outcomes.

Dr. Maryam Nakhjavani
Dr. Amanda R. Townsend
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• triple-negative breast cancer
• metastasis
• relapse
• molecular target
• gene expression
• treatment
• animal model
• clinical outcome